Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

CTNMBearishIndustry Newsnews

High materiality8/10

CTNM Drops After Phase 2 MOONLIGHT-1 Misses Primary Endpoint

Sep 15, 2026, 12:22 PM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

A Phase 2 failure in a partner-backed program undermines near-term catalysts and can trigger multiple compression factors (valuation, risk premium, and potential renegotiation risk). Historical biotech shocks from trial results often lead to rapid downside followed by choppier recovery as new data or pivot options emerge.

AI summary

What happened, with direct paths to the underlying reporting

Contineum Therapeutics fell after Phase 2 MOONLIGHT-1 failed to meet the primary endpoint for JNJ-5120/PIPE-307 in major depressive disorder. Johnson & Johnson is reviewing the data, including exploratory endpoints, to determine next steps under the license. While the longer-term setup looks constructive, near-term action will hinge on reclaiming the 50-day line and key supports.

CTNM slides after Phase 2 MOONLIGHT-1 misses primary endpoint in MDD.
JNJ evaluating data and prespecified endpoints to decide next steps.
Long-term trend intact; 50-/200-day cross supports potential rebound.
Resistance at 15.34; support near 13.60 (200-day SMA).
Premarket dip tied to risk-off tone, company news driver.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.